NWBO — Northwest Biotherapeutics Share Price
Last trade - 00:00- $489.55m
- $565.55m
- $1.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 354.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -5853.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.29 | 1 | 1.68 | 1.93 | 1.38 | n/a | n/a | -10.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
Directors
- Linda Powers CHM (65)
- Leslie Goldman SVP (75)
- Marnix Bosch CTO (62)
- Alton Boynton CSO (76)
- Jerry Jasinowski LED (82)
- J. Cofer Black IND (71)
- Navid Malik IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 29th, 1998
- Public Since
- December 14th, 2001
- No. of Shareholders
- 46,428
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,390,753,061
- Address
- SUITE 800, 4800 MONTGOMERY LANE, BETHESDA, 20814
- Web
- https://nwbio.com/
- Phone
- +1 2404979024
- Auditors
- Cherry Bekaert LLP
Latest News for NWBO
Upcoming Events for NWBO
Q1 2025 Northwest Biotherapeutics Inc Earnings Release
Northwest Biotherapeutics Inc Annual Shareholders Meeting
Q2 2025 Northwest Biotherapeutics Inc Earnings Release
Similar to NWBO
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 22:21 UTC, shares in Northwest Biotherapeutics are trading at $0.35. This share price information is delayed by 15 minutes.
Shares in Northwest Biotherapeutics last closed at $0.35 and the price had moved by -29.75% over the past 365 days. In terms of relative price strength the Northwest Biotherapeutics share price has underperformed the S&P500 Index by -33.62% over the past year.
There is no consensus recommendation for this security.
Find out moreNorthwest Biotherapeutics does not currently pay a dividend.
Northwest Biotherapeutics does not currently pay a dividend.
Northwest Biotherapeutics does not currently pay a dividend.
To buy shares in Northwest Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.35, shares in Northwest Biotherapeutics had a market capitalisation of $489.55m.
Here are the trading details for Northwest Biotherapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NWBO
Based on an overall assessment of its quality, value and momentum Northwest Biotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Northwest Biotherapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +27.67%.
As of the last closing price of $0.35, shares in Northwest Biotherapeutics were trading +20.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Northwest Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Northwest Biotherapeutics' management team is headed by:
- Linda Powers - CHM
- Leslie Goldman - SVP
- Marnix Bosch - CTO
- Alton Boynton - CSO
- Jerry Jasinowski - LED
- J. Cofer Black - IND
- Navid Malik - IND